Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA's $80 Bil. Contribution To Health Reform In The Crosshairs Once Again

This article was originally published in The Pink Sheet Daily

Executive Summary

For the second time, Sen. Bill Nelson, D-Fla., will try to pass an amendment to close the Medicare Part D coverage gap, effectively breaking the $80 billion PhRMA deal by boosting drug discounts.

You may also be interested in...



Rx Price Hikes In Advance Of Health Bill Will Get OIG Probe

Sen. Bill Nelson continues campaign to extract more concessions from pharmaceutical industry as part of health care reform legislation.

Rx Price Hikes In Advance Of Health Bill Will Get OIG Probe

Sen. Bill Nelson continues campaign to extract more concessions from pharmaceutical industry as part of health care reform legislation.

Dorgan Drug Importation Amendment Has White House In Thorny Position

An amendment being debated on the Senate floor that would allow consumers to import prescription drugs from other countries creates a particularly thorny situation for the White House: while President Obama was a co-sponsor of the measure when he was still a freshman senator, his support of it now would effectively break the $80 billion deal he brokered with the pharmaceutical industry

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel